Reducing blood pressure in mid-life adults who binge drink
Reducing Blood Pressure in Mid-life Adult Binge Drinkers: the Role of Microvascular Function and Sympathetic Activity
This study is testing whether an 8-week exercise program can help mid-life adults who binge drink lower their blood pressure and improve their overall health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 55 (estimated) |
| Ages | 50 Years to 64 Years |
| Sex | All |
| Sponsor | The University of Texas at Arlington Academic / other |
| Locations | 1 site (Arlington, Texas) |
| Trial ID | NCT05522075 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between blood pressure, microvascular function, and sympathetic nerve activity in mid-life adult binge drinkers compared to alcohol abstainers and moderate drinkers. In the first phase, baseline assessments will be conducted to gather data on these parameters. The second phase involves an 8-week aerobic exercise training program specifically for binge drinkers, with follow-up measurements to evaluate the impact of the intervention on their health metrics.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 50-64 who binge drink, abstain from alcohol, or drink moderately.
Not a fit: Patients with a history of cardiovascular disease, diabetes, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to effective interventions for reducing blood pressure and improving cardiovascular health in mid-life binge drinkers.
How similar studies have performed: While there have been studies on exercise and alcohol consumption, this specific approach targeting mid-life binge drinkers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women (50-64 years of age) who do not drink alcohol, who drink at moderate levels, or who binge drink * Female subjects will be postmenopausal (i.e., cessation of menses for ≥1 yr). * Subjects who can speak and understand English. Exclusion Criteria: * a history of diabetes, cardiovascular disease, liver, or renal disease * current or history of smoking and illicit drug use * blood pressure ≥160/100 mm Hg * other known traditional cardiovascular disease risks: obesity (BMI≥35 kg/m2), or hyperlipidemia (total cholesterol\>230 mg/dl and/or LDL cholesterol\>160 mg/dl) * active infection (in the past 2 months) * a history of seizures, cancer, or inflammatory disease (i.e., gout or rheumatoid) * unstable body weight (\>5% change during the past 6 months) * regular aerobic exercise training (i.e., they engage in 30 min of structured aerobic exercise at least 3 times per week) * current use of hormone replacement therapy (i.e., estrogen, progesterone, and testosterone)
Where this trial is running
Arlington, Texas
- University of Texas at Arlington — Arlington, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Chueh-Lung Hwang, PhD — University of Texas at Arlington
- Study coordinator: Chueh-Lung Hwang, PhD
- Email: chuehlung.hwang@uta.edu
- Phone: 8172729722
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.